0
selected
-
1.
Novel nutraceutical supplements with yeast β-glucan, prebiotics, minerals, and Silybum marianum (silymarin) ameliorate obesity-related metabolic and clinical parameters: A double-blind randomized trial.
Nehmi-Filho, V, Santamarina, AB, de Freitas, JA, Trarbach, EB, de Oliveira, DR, Palace-Berl, F, de Souza, E, de Miranda, DA, Escamilla-Garcia, A, Otoch, JP, et al
Frontiers in endocrinology. 2022;13:1089938
-
-
-
Free full text
Plain language summary
Obesity is a growing concern around the world and. There are several factors that contribute to its development such as genetics, lack of exercise and poor diet. Interest in food supplements and nutraceuticals is growing as a strategy to treat and prevent obesity. This randomised control trial of 59 individuals aimed to determine whether a nutritional supplement containing yeast beta-glucan, prebiotics, minerals, and S. marianum (Silymarin) had any effect on obesity related body biochemistry and metabolism. The results showed that body morphology and enzymes associated with non-alcoholic fatty liver disease, which is a disease associated with obesity, were improved with supplementation. In addition, levels of stress hormones and hormones associated with metabolism were improved. It was concluded that supplementation with yeast beta-glucan, prebiotics, minerals, and Silymarin may be of benefit to individuals with obesity to improve associated diseases and metabolism. This study could be used by healthcare professionals to understand that supplementation may be of benefit to individuals with obesity.
Abstract
PURPOSE It is known that obesity has a multifactorial etiology that involves genetic and environmental factors. The WHO estimates the worldwide prevalence of 1.9 billion overweight adults and more than 650 million people with obesity. These alarming data highlight the high and growing prevalence of obesity and represent a risk factor for the development and aggravation of other chronic diseases, such as nonalcoholic fatty liver disease (NAFLD) that is frequently considered the hepatic outcome of type 2 diabetes. The use of non-pharmacological therapies such as food supplements, nutraceuticals, and natural integrative therapies has grown as an alternative tool for obesity-related diseases compared to conventional medications. However, it is a still little explored research field and lacks scientific evidence of therapeutic effectiveness. Considering this, the aim is to evaluate whether a new nutraceutical supplement composition can improve and supply essential mineral nutrients, providing an improvement of obesity-related metabolic and endocrine parameters. METHODS Sedentary volunteers (women and men) with body mass index (BMI) ≤34.9 kg/m2 were divided into two groups: Novel Nutraceutical Supplement_(S) (n = 30) and Novel Nutraceutical Supplement (n = 29), differing in the absence (S) or presence of silymarin, respectively. Volunteers were instructed to take two capsules in the morning and two capsules in the evening. No nutritional intervention was performed during the study period. The data (anthropometrics and anamneses) and harvest blood (biochemistry and hormonal exams) were collected at three different time points: baseline time [day 0 (T0)], day 90 (T90), and day 180 (T180) post-supplementation. RESULTS In the anthropometric analysis, the waist circumference in middle abdomen (WC-mid) and waist circumference in iliac crest (WC-IC) were reduced. Also, the waist-to-height ratio (WHt R) and waist-to-hip ratio (WHR) seem to slightly decrease alongside the supplementation period with both nutraceutical supplements tested as well as transaminase enzyme ratio [aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio (AAR)], a known as a biomarker of NAFLD, and endocrine hormones cortisol and thyroid-stimulating hormone (TSH) at 90 and 180 days post-supplementation. CONCLUSIONS In a condition associated with sedentary and no nutritional intervention, the new nutraceutical supplement composition demonstrated the ability to be a strong and newfangled tool to improve important biomarkers associated with obesity and its comorbidities.
-
2.
Obesity-related inflammatory modulation by juçara berry (Euterpe edulis Mart.) supplementation in Brazilian adults: a double-blind randomized controlled trial.
Santamarina, AB, Jamar, G, Mennitti, LV, Cesar, HC, Vasconcelos, JR, Oyama, LM, de Rosso, VV, Pisani, LP
European journal of nutrition. 2020;(4):1693-1705
Abstract
PURPOSE Obesity is an inflammatory-related disease, which recruits immune system cells triggering to imbalanced production of cytokines. Obesity management and treatment using foods bioactive compounds have gained clinical and scientific relevance. Juçara (Euterpe edulis Mart.) fruit is rich in fibers, unsaturated lipids and, anthocyanins showing potential health benefits. Thus, we investigated the effect of juçara pulp intake on inflammatory status of monocytes from obese individuals. METHODS It is a placebo-controlled, randomized double-blind trial. Twenty-seven obese participants (BMI between 30.0 and 39.9 kg/m2) of both genders from 31 to 59-year-old, divided into two groups: 5 g juçara freeze-dried pulp or 5 g of placebo for 6 weeks. Before and after supplementation, blood samples were collected and monocytes obtained and stimulated with lipopolysaccharides. After 24 h of incubation, the cells and supernatants were analyzed. RESULTS Post-treatment, juçara reduced TLR4, and IL-6 mRNA compared to placebo. Juçara also increased IL-10 mRNA in post-treatment. The protein expression of TLR4 pathway post-treatment, MYD88 expression reduced in juçara group compared to placebo. The juçara post-treatment reduced pIKKα/β compared to the placebo. Ob-R protein levels were higher in the juçara group post-treatment compared to pre-treatment. IL-6, TNF-α, and MCP-1 production by monocytes were reduced by juçara in post-treatment compared to pre-treatment levels. The supplementation increased IL-10 in juçara group with LPS compared to pre-treatment and versus juçara group without LPS. CONCLUSION These results demonstrated a proinflammatory state at the beginning, which was improved by juçara pulp consumption. Our results suggest juçara pulp as a potential tool against the proinflammatory status of obesity.
-
3.
Prebiotic potencial of juçara berry on changes in gut bacteria and acetate of individuals with obesity.
Jamar, G, Santamarina, AB, Casagrande, BP, Estadella, D, de Rosso, VV, Wagner, R, Fagundes, MB, Pisani, LP
European journal of nutrition. 2020;(8):3767-3778
Abstract
PURPOSE Whole plant foods can be fermentable by SCFA-producing bacteria and positively influence host adipose tissue development and obesity related-metabolic disorders, conferring a prebiotic role. Considering the juçara berry composition, rich in fiber and polyphenols, we hypothesized the probable prebiotic role of juçara in individuals with obesity. METHODS It was a randomized double-blind placebo-controlled trial with 35 volunteers with obesity I and II of both sexes aged from 31 to 59 years, divided into juçara group (5 g lyophilized juçara) or placebo group (5 g of maltodextrin) for 6 weeks. Before and after supplementation, food intake and blood and stool samples were collected to evaluate serum LPS, SCFA, and microbial bacteria. RESULTS Significant increase in fecal acetate (g = 0.809; p = 0.038) and in relative abundance of A. muciniphila, Bifidobacterium spp. and C. coccoides were observed in response to juçara supplementation (Δ% = 239.6%, 182.6%, and 214%, respectively), with a significant mediator role of Bifidobacterium spp. in high amounts of fecal acetate (z = 2.925; p = 0.003). To certify the prebiotic role of juçara, the averages were adjusted for total fiber intake; and there was no effect of the fiber intake on the SCFA nor on the intestinal bacteria. CONCLUSION Juçara berry may haveprebiotic function, with emphasis on the bifidogenic effect, leading to increased excretion of acetate.
-
4.
Relationship between fatty acids intake and Clostridium coccoides in obese individuals with metabolic syndrome.
Jamar, G, Santamarina, AB, Dias, GC, Masquio, DCL, de Rosso, VV, Pisani, LP
Food research international (Ottawa, Ont.). 2018;:86-92
Abstract
Dietary habits exert a strong influence on gut microbial composition and may result in an imbalance of gut microbes, representing a predisposition to obesity and metabolic disorders. We aimed to investigate a potential relationship between gut bacterial species and metabolic parameters and dietary intake. Bacterial DNA was extracted from feces of 34 obese subjects with and without metabolic syndrome (MS and n-MS group, respectively). We then used real-time polymerase chain reaction (qPCR) for quantifying specific sequences to Akkermansia muciniphila, Bifidobacterium spp., Clostridium coccoides, and Lactobacillus spp. and analyzed them with respect to clinical characteristics. Our data showed that the MS group had a 6.7-fold higher level of C. coccoides in their stool samples than the n-MS group. The abundance of C. coccoides was positively correlated with a high intake of monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids. Furthermore, an excessive dietary level of MUFA was identified as a predictor of C. coccoides abundance. Alterations in the gut microbial ecology were positively correlated with levels of triacylglycerol in obese individuals. Therefore, the type and quantity of dietary fat may alter the gut microbial ecology in obese individuals with MS and may predispose them to dyslipidemia.
-
5.
Supplementation of Juçara Berry (Euterpe edulis Mart.) Modulates Epigenetic Markers in Monocytes from Obese Adults: A Double-Blind Randomized Trial.
Santamarina, AB, Jamar, G, Mennitti, LV, de Cássia César, H, de Rosso, VV, Vasconcelos, JR, Oyama, LM, Pisani, LP
Nutrients. 2018;(12)
Abstract
Nutrigenomics is an emerging field in obesity since epigenetic markers can be modified by environmental factors including diet. Considering juçara composition-rich in anthocyanins, monounsaturated fatty acids (MUFAs) and fibers-it has the potential for epigenetic modulation. We evaluated the juçara supplementation modulating the serum fatty acids profile and epigenetic markers in monocytes of adult obese humans. It was a randomized double-blind, controlled trial with 27 obese (Body mass index between 30.0 and 39.9 kg/m²) participants of both genders aged from 31 to 59 years, divided into juçara group (5 g juçara freeze-dried pulp) or placebo group (5 g of maltodextrin) for 6 weeks. Before and after supplementation, blood samples were collected. The serum and monocytes cells obtained were cultured and stimulated with lipopolysaccharides as proinflammatory stimulus. After 24 h of incubation, the cells and supernatants were collected and analyzed. Juçara improved the serum fatty acids profile on unsaturated fatty acids levels. The epigenetic markers evaluated were improved post-treatment. Also, the methylated DNA level was increased after treatment. We find that juçara supplementation is a predictor of methyl CpG binding proteins 2 (MeCP2) in monocytes. Concluding, juçara supplementation improved the serum fatty acids profile, modulating the epigenetic markers in monocytes from obese individuals.
-
6.
The role of free fatty acids in the inflammatory and cardiometabolic profile in adolescents with metabolic syndrome engaged in interdisciplinary therapy.
Masquio, DC, de Piano-Ganen, A, Oyama, LM, Campos, RM, Santamarina, AB, de Souza, GI, Gomes, AD, Moreira, RG, Corgosinho, FC, do Nascimento, CM, et al
The Journal of nutritional biochemistry. 2016;:136-44
Abstract
The purpose of the present study was to evaluate if interdisciplinary therapy can influence the cardiometabolic and serum free fatty acid profile. The second aim was to evaluate if there is an association between serum free fatty acids, inflammation and cardiometabolic biomarkers in obese adolescents with and without metabolic syndrome submitted to a long-term interdisciplinary therapy. The study involved 108 postpuberty obese adolescents, who were divided according to metabolic syndrome (MetS) diagnosis: MetS (n=32) and Non-MetS (n=76). The interdisciplinary therapy consisted of a 1-year period of nutrition, psychology, physical exercise and clinical support. After therapy, both groups improved metabolic, inflammatory (leptin, adiponectin, leptin/adiponectin ratio, adiponectin/leptin ratio and C-reactive protein) and cardiometabolic profile (PAI-1 and ICAM). Metabolic syndrome prevalence reduced from 28.70% to 12.96%. Both groups reduced myristic acid (C14:0) and increased docosahexaenoic acid (DHA, C22:6n3), heneicosapentaenoic acid (HPA, C21:5n3) and arachidonic acid (C20:4n6). After adjustment for metabolic syndrome and the number of metabolic syndrome parameters, multiple regression analysis showed that changes in VCAM and PAI-1 were negatively associated with changes in cis-linoleic acid (C18:2n6c). Additionally, changes in trans-linoleic acid (C18:2n6t) were also positively associated with these biomarkers. Moreover, leptin and leptin/adiponectin ratio were negatively associated with changes in docosapentaenoic acid (DPA, C22:5n3) and stearidonic acid (SDA, C18:4n3). Adiponectin/leptin ratio was positively associated with docosapentaenoic acid (DPA, C22:5n3). Changes in adiponectin were positively correlated with changes in omega 3, such as heneicosapentaenoic acid (HPA, C21:5n3) and docosapentaenoic acid (DPA, C22:5n3). Results support that interdisciplinary therapy can control inflammatory and cardiometabolic profile in obese adolescents. Moreover, serum fatty acids can be influenced by lifestyle changes and are able to modulate these biomarkers.